The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIDH.L Regulatory News (IDH)

  • There is currently no data for IDH

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8.3 - Immunodiagnostic Systems Holdings Plc

18 May 2021 14:16

Norges Bank - Form 8.3 - Immunodiagnostic Systems Holdings Plc

Norges Bank - Form 8.3 - Immunodiagnostic Systems Holdings Plc

PR Newswire

London, May 18

FORM 8.3

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY

A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

Rule 8.3 of the Takeover Code (the “Code”)

1. KEY INFORMATION

(a) Full name of discloser:Norges Bank
(b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.N/A
(c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offereeIMMUNODIAGNOSTIC SYSTEMS HLD
(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:N/A
(e) Date position held/dealing undertaken: For an opening position disclosure, state the latest practicable date prior to the disclosureOpening disclosure 17/05/2021
(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer? If it is a cash offer or possible cash offer, state “N/A”No Not required

2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

Class of relevant security:10p ordinary
InterestsShort positions
Number%Number%
(1) Relevant securities owned and/or controlled:607,7322.11%
(2) Cash-settled derivatives:
(3) Stock-settled derivatives (including options) and agreements to purchase/sell:
TOTAL:607,7322.11%

All interests and all short positions should be disclosed.

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

(b) Rights to subscribe for new securities (including directors’ and other employee options)

Class of relevant security in relation to which subscription right exists:
Details, including nature of the rights concerned and relevant percentages:

3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

Purchases and sales

Class of relevant securityPurchase/saleNumber of securitiesPrice per unit

(b) Cash-settled derivative transactions

Class of relevant securityProduct description e.g. CFDNature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short positionNumber of reference securitiesPrice per unit

(c) Stock-settled derivative transactions (including options)

(i) Writing, selling, purchasing or varying

Class of relevant securityProduct description e.g. call optionWriting, purchasing, selling, varying etc.Number of securities to which option relatesExercise price per unitType e.g. American, European etc.Expiry dateOption money paid/ received per unit

(ii) Exercise

Class of relevant securityProduct description e.g. call optionExercising/ exercised againstNumber of securitiesExercise price per unit

(d) Other dealings (including subscribing for new securities)

Class of relevant securityNature of dealing e.g. subscription, conversionDetailsPrice per unit (if applicable)

4. OTHER INFORMATION

(a) Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none”

(b) Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or (ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced: If there are no such agreements, arrangements or understandings, state “none”

(c) Attachments

Is a Supplemental Form 8 (Open Positions) attached?NO

Date of disclosure:18/05/2021
Contact name:Aïssata Diakhite
Telephone number:+4724073000

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk. The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.

Date   Source Headline
29th Oct 20077:00 amRNSNotice of Results
5th Oct 200712:11 pmRNSNotifiable Interest
2nd Oct 20077:01 amRNSSenior Management Appointment
17th Sep 20073:33 pmRNSNotifiable Interest
17th Sep 20077:01 amRNSBoard Appointment
10th Sep 20073:48 pmRNSNotifiable Interest
3rd Sep 20077:01 amRNSTotal Voting Rights
3rd Sep 20077:00 amRNSCompletion of Acquisition
31st Aug 20073:16 pmRNSAGM Statement
28th Aug 20071:48 pmRNSResult of EGM
20th Aug 200712:36 pmRNSNotifiable Interest
20th Aug 20079:53 amRNSAIM Rule 26
3rd Aug 20077:00 amRNSProposed Acquisition
31st Jul 200711:03 amRNSTotal Voting Rights
26th Jul 20077:01 amRNSCompletion of acquisition
16th Jul 20075:57 pmRNSCorrection re. dividend dates
16th Jul 20077:01 amRNSFinal Results
29th Jun 20077:01 amRNSNotice of Results
18th Jun 20077:02 amRNSImmunoassay kits agreement
8th May 20077:01 amRNSNotifiable Interest
3rd May 20073:39 pmRNSDirectors Dealing
21st Mar 20077:00 amRNSTrading Statement
20th Mar 20075:33 pmRNSNotifiable Interest
13th Mar 20077:00 amRNSBoard Appointment
12th Feb 20077:02 amRNSBoard Appointment
31st Jan 20077:02 amRNSProduct launch
4th Jan 20077:00 amRNSProduct Launch
21st Dec 200612:48 pmRNSTotal Voting Rights
5th Dec 20069:44 amRNSDirector/PDMR Shareholding
4th Dec 20067:02 amRNSAutomation agreement
15th Nov 20068:54 amRNSHolding(s) in Company
6th Nov 20067:01 amRNSInterim Results
19th Oct 200611:34 amRNSNotice of Results
10th Oct 20067:02 amRNSIDS launches into Austria
13th Sep 20067:00 amRNSLaunch of new assay kit
22nd Aug 200611:04 amRNSAGM Statement
17th Jul 20064:35 pmRNSHolding(s) in Company
5th Jul 20067:00 amRNSFinal Results
30th May 20067:03 amRNSMarketing & sales agreement
15th May 20067:01 amRNSDirectorate Change
12th Apr 20067:01 amRNSDirector/PDMR Shareholding
30th Mar 20067:01 amRNSPre-close Trading update
21st Feb 20062:38 pmRNSDirectors Dealing
7th Nov 20057:00 amRNSInterim Results
26th Oct 20059:52 amRNSNotice of Results
26th Sep 20057:01 amRNSBoard Appointment
6th Sep 200511:18 amRNSAGM Statement
12th Aug 200510:42 amRNSFDA Approval
12th Jul 20057:01 amRNSFinal Results
6th Jul 20053:19 pmRNSNotice of Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.